Skip to content

VIREMED

Active Private limited companyfounded 2020active for 6 yearsMolenveld 61, 3650 Dilsen-StokkemKBO/BCE: BE 0741.597.167 #8 company by equity in Dilsen-Stokkem, Health and social work sector
VIREMED
Follow ReportCompare

Overview

Lifetime

6 annual accounts with figures on one time axis
peak €152,060 (2025)
€152,060▲ 12.1%
peak €106,690 (2025)
€106,690▲ 18.3%
peak €468,367 (2025)
€468,367▲ 8.3%
€149,743▲ 270%
Board1 name since 2020
1 directorVERBEECK Tine Petra Maria Lucie
Documentsfilings and deeds
10-06-202651 days before the deadline
2025micro format
Gross margin from €135,658 to €152,060Dividend €70,631Debts from €40,427 to €149,743Cash from €223,799 to €453,000

Key points

from the 2025 annual accounts

Equity

€468,367 ▲ 8.3%
432,3082024+106,690Profit-70,631Dividend468,3672025

VIREMED paid out €70,631 in dividends. That is 66% of the 2025 profit.

Turnover

≈ €300,000 estimated

The micro format states no turnover.

Debts

€149,743 ▲ 270%
Other debts
+71,844
Suppliers
+35,324
Taxes and wages
+2,149

Debts rose by €109,316 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.

Liquidity

4.12 was 11.46 in 2024

Short-term debts rose from €40,427 to €149,743.

Filings

6 annual accounts 4 late
AprilJune31 JulyOctober202020222024

The 2021 accounts came latest: 31 days after the end of the period.

Position in the sector

€468,367

More equity than 80% of companies in human health. Sector median €124,552 · 20,762 companies.

Checked score

95
Excellent
Financially stronger than 63% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

The dashed line is the sector median: < 0.1% across 24,185 companies (NACE 86, micro).

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 12-2024: < 0.1% 01-2025: < 0.1%● unchanged vs 12-2024 02-2025: < 0.1%● unchanged vs 01-2025 03-2025: < 0.1%● unchanged vs 02-2025 04-2025: < 0.1%● unchanged vs 03-2025 05-2025: < 0.1%● unchanged vs 04-2025 06-2025: < 0.1%● unchanged vs 05-2025 07-2025: < 0.1%● unchanged vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025highest value 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026lowest value 08-2026: < 0.1%● unchanged vs 07-2026lowest value 09-2026: < 0.1%● unchanged vs 08-2026lowest value 10-2026: < 0.1%● unchanged vs 09-2026lowest value 11-2026: < 0.1%● unchanged vs 10-2026lowest value

Financial strength
Strong

100=equity 75.8% of total assets
91-9short-term debt 24.2% · cash 73.3%
90-3return on assets 17.3%

Score breakdown

lowers risk
Sector: Human health activities (NACE 86)
Liquidity: current ratio 4.12, cash €453,000
Size: total assets €618,111
Equity €468,367 (75.8% of total assets)
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 76% on liquidity, 46% on profitability and 50% on growth.

The bankruptcy probability was computed on 08-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

The probability rests on the annual accounts with balance sheet date 31-12-2025.

Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Comparable companies, two years later

In July 2024, 6,782 companies had the same profile as VIREMED has now. Each dot stands for 17 companies, two years later.

96.7%
were still trading
2.7%
stopped another way
0.6%
went bankrupt
  • Small
  • 5 to 10 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

That fits the bankruptcy probability of VIREMED itself: < 0.1% within 12 months.

Test of the method

The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 6,782 companies, not a prediction for VIREMED. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit of up to €40,000 on 30-day terms is acceptable

Liquidity is ample, with a current ratio of 4.12 (11.46 in 2024), above the usual 1.5. Short-term debt is 24.2% and cash 73.3% of total assets. 24.2% of the assets are financed with debt and provisions.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

5 signals, none raises the risk
Five signals.
lowers riskneutral
lowers risk · Sector: Human health activities (NACE 86)
KBO
lowers risk · Liquidity: current ratio 4.12, cash €453,000
NBB · annual accounts
lowers risk · Size: total assets €618,111
Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
lowers risk · Equity €468,367 (75.8% of total assets)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-06-2026, 51 days ahead of the deadline.
NBB · 6 filings
Deviation from the deadline
2025
51 days early
2024
28 days late
2023
2 days early
2022
30 days late
2021
31 days late
2020
27 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 6 accounts on average 11 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 28 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
08-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Board and ownership

VT
VERBEECK Tine Petra Maria Lucie
Director, since 15-01-2020
  • VERBEECK Tine Petra Maria Lucie founderdeed of 17-01-2020
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0741597167
Incorporation Founder: VERBEECK Tine Petra Maria Lucie · Founding capital of €5,000, 500 shares · Appointment: VERBEECK Tine Petra Maria Lucie (director) · published on 17-01-2020 · Gazette deed
First establishment Dorpsstraat 7 R, Dilsen-Stokkem
All 13 events

Comparable companies

same main activity, similar in size and age
Company
VIREMED Dilsen-Stokkem €618,111 €152,060 75.8% -
DOKTERSPRAKTIJK SAVENAY SOPHIE Sint-Truiden €698,234 €157,881 46.0% -
Dr. Katrien Butaye huisarts Leuven €578,014 €157,041 95.3% -
SUSYBAT Etterbeek €551,884 €154,371 5.5% -
Geert Laire MD Mechelen €571,164 €155,543 90.2% -
Dokter Lore Wittevrongel Denderleeuw €564,068 €149,554 7.6% -
Dr. WILLY STAESSEN Diksmuide €545,019 €148,631 93.8% -

These companies have the same main activity as VIREMED: general medical practice (NACE 86210). They are comparable in size and age: total assets between €545,000 and €698,000, founded between 2019 and 2020.

Official details

Source: KBO
Status
Active since 15-01-2020Normal situation
Activity
General medical practiceNACE 86210and 1 other
Establishment unit
2.298.171.1143650 Dilsen-Stokkem, since 15-01-2020
Financial year end
31 December
Peppol
Reachable since 29-07-2024
Company details

Annual accounts 2025

€152,060▲ 12.1%
€106,690▲ 18.3%
€468,367▲ 8.3%
€618,111▲ 30.8%
Filing
Filed on 10-06-2026, 51 days before the end of the filing period
Financials

Insights on VIREMED

VIREMED files the micro format. That format states no turnover. The gross margin rose from €102,087 in 2020 to €152,060 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

micro format, filed on 10-06-2026, 51 days before the deadline
€152,060
▲ 12.1%
€142,955
▲ 12.9%
€106,690
▲ 18.3%
€467,599
▲ 10.6%
75.8%
▼ 15.7 percentage points
4.12
▼ 7.34

Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.

Turnover ≈ €300,000. Estimated: probably between €230,000 and €380,000.

In the rankings #8 company by equity in Dilsen-Stokkem, Health and social work sector#10 company by total assets in Dilsen-Stokkem, Health and social work sector

Balance sheet

balance sheet total €618,111 on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

Compare with sector

75.8%

Higher than 64% of 20,760 companies in 2025.

4.12

Higher than 63% of 20,335 companies in 2025.

17.3%

Higher than 43% of 20,616 companies in 2025.

VIREMED Middle half of the sector 80% of the sector Micro accounts in human health (NACE 86)

Net result: middle half · Equity: top quarter · Balance sheet total: top quarter · Working capital: top quarter

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend202520242023202220212020
Balance sheet: assets
20/58 618,111472,735414,855388,046254,845119,213
21/28 7689,35917,97726,59632,9831,952
22/27 7689,35917,97726,59632,9831,952
23 5339581,3831,807--
24 2358,40116,59524,78932,9831,952
29/58 617,343463,376396,878361,450221,862117,261
40/41 11,42513,32414,3439,50812,55152,546
40 5,1796,1876,3489,50812,55152,546
41 6,2467,1387,996---
50/53 152,478226,08652,72748,834--
54/58 453,000223,799329,641302,959209,16564,120
490/1 440167167149147594
Balance sheet: equity and liabilities
10/49 618,111472,735414,855388,046254,845119,213
10/15 468,367432,308342,148255,846164,75875,631
10/11 5,0005,0005,0005,0005,0005,000
13 463,367427,308337,148250,846159,75870,631
133 463,367427,308337,148250,846159,75870,631
14 000---
17/49 149,74340,42772,707132,20090,08743,582
42/48 149,74340,42772,707132,20090,08741,082
44 51,67216,34811,41937,7407,42111
440/4 51,67216,34811,41937,7407,42111
45 8,5496,40041,09575,82066,22529,499
450/3 8,5494,20038,39573,12063,72529,499
454/9 02,2002,7002,7002,500-
47/48 89,52317,67920,19318,64016,44111,572
492/3 -----2,500
Income statement
9900 152,060135,658136,237139,112134,480102,087
630 8,5918,6198,6198,5117,9591,528
640/8 515449446534600785
9901 142,955126,590127,172130,068125,92199,774
75/76B 9,4632,747138---
75 9,4632,747138---
65/66B 2,0693,1502,0182,8351,5681,144
65 2,0693,1502,0182,8351,5681,144
9903 150,349126,187125,292127,232124,35398,630
67/77 43,65936,02733,99036,14535,22527,999
9904 106,69090,16091,30291,08889,12870,631
9905 106,69090,16091,30291,08889,12870,631
Appropriation of the result
9906 106,69090,16091,30291,08889,12870,631
791/2 70,631-----
691/2 106,69090,16086,30291,08889,12870,631
6921 106,69090,16086,30291,08889,12870,631
694/7 70,63105,000---
694 70,631-----
695 -05,000---
Document PDFPDFPDFPDFPDFPDF

The notes to these accounts have 5 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).

Source: Annual accounts 2025 (PDF), filed on 10-06-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2025 micro format 10-06-2026 2026-00150142 PDF
31-12-2024 micro format 28-08-2025 2025-00427795 PDF
31-12-2023 micro format 29-07-2024 2024-00317265 PDF
31-12-2022 micro format 30-08-2023 2023-00377734 PDF
31-12-2021 micro format 31-08-2022 2022-20398008 PDF
31-12-2020 micro format 27-08-2021 2021-55500518 PDF

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend202520242023202220212020
151,545135,209135,790138,579133,880101,302
115,28198,77999,92199,59897,08772,159
0002,12438,9901,980
229,200-105,84126,68193,794145,045-
467,599422,949324,171229,250131,77576,179
75.8%91.4%82.5%65.9%64.7%63.4%
4.1211.465.462.732.462.85
0.320.090.210.520.550.58
22.8%20.9%26.7%35.6%54.1%93.4%
17.3%19.1%22.0%23.5%35.0%59.2%
73.2642.9267.2948.8785.39-

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Investments

fixed assets acquired
Item20252024202320222021
Tangible fixed assets---€2,124€38,990
€8,591€8,619€8,619€8,511€7,959

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on VIREMED

The operating result for 2025 is 13% higher than in 2024 and the highest since 2020. It is a recovery after the fall in 2024.

Debt's share of the balance-sheet total rises from 8.6% to 24.2%. Equity and debt are higher.

Board & ownership

Board

1 director, since incorporation
VERBEECK Tine Petra Maria Lucie
Director (not named in the articles)
since 15-01-2020 term without a fixed end
listed in the 2025 annual accounts, filed on 10-06-2026

Office holders in the KBO →

Mandates through the years

1 name, the dashed line is today
VERBEECK Tine Petra Maria Lucie
Director (not named in the articles)
Board
Mandates as a list
  • VERBEECK Tine Petra Maria Lucie
    • Director (not named in the articles), from 09-01-2020 to date

See the board, name and registered office on a given date →

Control

Founder
VERBEECK Tine Petra Maria Lucie
This company
VIREMED
Equity €468,367
Profit €106,690 in 2025

Capital

Contribution
€5,000
Source
2025 annual accounts

Articles of association

deed of 17-01-2020 (in Dutch)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Board ruleThese rules set how the board is made up, meets and takes decisions.
“Kunnen hoedanigheid statutair bestuurder hebben indien benoemd in statuten, algemene vergadering die benoemt bepaalt aantal,duur opdracht en…”
“Bestuurder, tenzij de algemene vergadering anders beslist”
Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
“Overnemer moet arts zijn bevoegd in België en in kader vennootschap actief uitoefent of zal uitoefenen, garantie dat medische dossiers…”
Share issue ruleThe articles set how and by whom new shares are issued.
“Orgaan dat overgaat tot uitgifte bepaalt opening en tijdvak, nieuwe aandelen waarop in geld wordt ingeschreven eerst aangeboden aan…”
Statutory auditorA statutory auditor is a registered auditor who checks the annual accounts. Small companies need not have one. According to the deed, the legal criteria do not require one here.
No statutory auditor

Founder

At incorporation deed of 17-01-2020 ↗
  • VERBEECK Tine Petra Maria Lucie sole founder · 100% at incorporation

Network & group

No group

VIREMED has no parent and no holdings in its annual accounts. VERBEECK Tine Petra Maria Lucie is the only director.

At the same address

Molenveld 61, 3650 Dilsen-Stokkem · 1 other company
IO-Things
registered office since 03-03-2020 · founded in 2020
 total assets €366,136 (2025)
0744.681.173

Connections & network

1 connected company
Depth

The connected companies are in the list below.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
Huisartsenkring Maasland
via VERBEECK Tine Petra Maria Lucie · Director · deed of 03-09-2026
Founded in 1981
→

Timeline

Timeline

13 events since 2020

Deadline for the 2026 accounts: 31-07-2027

2026
Annual accounts 2025 filed PDFmicro format · 51 days before the deadline
2025
Highest result from 2020 to 2025 net €106,690 ▲18.3% The operating result of €142,955 and the net result of €106,690 are both a record.
Annual accounts 2024 filed PDFmicro format · 28 days late
2024
Liquidity more than doubled current ratio 11.46 The current ratio rises from 5.46 to 11.46. Short-term debt falls from €72,707 to €40,427.
Annual accounts 2023 filed PDFmicro format · 2 days before the deadline
Registered in the Peppol Directory Reachable for e-invoices through 0208:0741597167
2023
Annual accounts 2022 filed PDFmicro format · 30 days late
2022
Equity above €200,000 equity €255,846 ▲55.3% With a profit in every financial year since 2020, equity grows to €255,846.
Annual accounts 2021 filed PDFmicro format · 31 days late
2021
Equity above €150,000 equity €164,758 ▲118% With a profit in every financial year since 2020, equity grows to €164,758.
Annual accounts 2020 filed PDFmicro format · 27 days late
2020
IncorporationFounder: VERBEECK Tine Petra Maria Lucie · Founding capital of €5,000, 500 shares · Appointment: VERBEECK Tine Petra Maria Lucie (director) · published on 17-01-20205 points ▸

Open the deed in the Belgian Official Gazette

First establishment Dorpsstraat 7 R, Dilsen-Stokkem

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

VIREMED was incorporated on 15 January 2020 as a private limited company.1 Since 2020, VERBEECK Tine Petra Maria Lucie has served as director.2 Total assets rose from €119,213 in 2020 to €618,111 in 2025.3

  1. 1KBO register
  2. 2National Bank, annual accounts 2025
  3. 3National Bank, annual accounts 2020 and 2025

Company details

Identity

Enterprise number
0741.597.167
VAT number
BE 0741.597.167
Peppol ID
0208:0741597167
Legal form
Private limited company
Status
Active, normal situation
Founded
15-01-2020
Financial year
ends on 31 December
Peppol
Reachable since 29-07-2024Follow this company and you will hear the next morning if it leaves the Peppol register.
Name
VIREMED in Dutch
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 17-01-2020 (in Dutch)
Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Vlaams Gewest”
deed of 17-01-2020 (in Dutch)

Activities

NACEBEL 2025
86210 General medical practice main activity
86995 Nutrition and dietetics services
Codes under NACEBEL 2008
86210 General medical practice main activity
86909 Human health activities
PurposeThe purpose describes the activities the company may carry out under its articles.
“De uitoefening van de geneeskunde door de arts-aandeelhouder met als specialisatie huisarts rekening houdend met de regelen van de medische…”
5 activities
  1. De uitoefening van de geneeskunde door de arts-aandeelhouder met als specialisatie huisarts rekening houdend met de regelen van de medische plichtenleer,en onder de specifieke beroepsaansprakelijkheid van de arts-aandeelhouder en de bijkomende aansprakelijkheid van de vennootschap. De activiteit omvat impliciet de inning van de erelonen door en voor de vennootschap
  2. Het verstrekken van medische adviezen,raadgevingen en expertisen
  3. Het inrichten van algemene diensten,die nuttig of nodig zijn voor de uitoefening van voornoemde activiteiten,met inbegrip van een medisch secretariaat
  4. De aankoop en het huren en/of leasen van alle medische apparatuur en machines,die noodzakelijk zijn om de bovenvermelde medische discipline uit te voeren
  5. De mogelijkheden scheppen om de arts-aandeelhouder toe te laten zich verder te bekwamen ten einde in haar discipline aan de spits van de evolutie te blijven
deed of 17-01-2020 (in Dutch)

Registered office and establishments

1 establishment
Establishment Since Unit number
Molenveld 61 registered office 3650 Dilsen-Stokkem
Dorpsstraat 7 R 3650 Dilsen-Stokkem 15-01-2020 2.298.171.114

Buildings and parcels at the addresses

Ground area
6,554 m²
Buildings
1,237 m²
Volume, LiDAR
6,893 m³
Tallest building
14.7 m
Buildings to scale, each on its own parcel
1,020 m², 14.7 m 1,020 m², 14.7 m

Location

registered office establishment The establishment unit on the map
2 companies at this address See who is registered here

Parcels

Cadastral parcelArea Buildings Height / floors
73043A0173/00H0005,057 m² 1 · 1,020 m² 14.7 m · 1
73081C0321/00C0001,497 m² 1 · 217 m² -

We would like to set cookies. That happens only with your consent. What we measure